Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT

Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the...

Full description

Bibliographic Details
Main Authors: Lena Thomas, Caroline Balmus, Hojjat Ahmadzadehfar, Markus Essler, Holger Strunk, Ralph A. Bundschuh
Format: Article
Language:English
Published: MDPI AG 2017-07-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/10/3/68
id doaj-044e79fa353041308a88ed4cb574e56a
record_format Article
spelling doaj-044e79fa353041308a88ed4cb574e56a2020-11-25T03:53:22ZengMDPI AGPharmaceuticals1424-82472017-07-011036810.3390/ph10030068ph10030068Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CTLena Thomas0Caroline Balmus1Hojjat Ahmadzadehfar2Markus Essler3Holger Strunk4Ralph A. Bundschuh5Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyRadiologische Klinik, Universitätsklinikum Bonn, Bonn D-53012, GermanyKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn D-53127, GermanyPurpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by 99mTc-MDP bone scan and 68Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied.https://www.mdpi.com/1424-8247/10/3/68prostate cancerbone scan indexbone scintigraphyPSMA-PET/CT
collection DOAJ
language English
format Article
sources DOAJ
author Lena Thomas
Caroline Balmus
Hojjat Ahmadzadehfar
Markus Essler
Holger Strunk
Ralph A. Bundschuh
spellingShingle Lena Thomas
Caroline Balmus
Hojjat Ahmadzadehfar
Markus Essler
Holger Strunk
Ralph A. Bundschuh
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
Pharmaceuticals
prostate cancer
bone scan index
bone scintigraphy
PSMA-PET/CT
author_facet Lena Thomas
Caroline Balmus
Hojjat Ahmadzadehfar
Markus Essler
Holger Strunk
Ralph A. Bundschuh
author_sort Lena Thomas
title Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
title_short Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
title_full Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
title_fullStr Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
title_full_unstemmed Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
title_sort assessment of bone metastases in patients with prostate cancer—a comparison between 99mtc-bone-scintigraphy and [68ga]ga-psma pet/ct
publisher MDPI AG
series Pharmaceuticals
issn 1424-8247
publishDate 2017-07-01
description Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by 99mTc-MDP bone scan and 68Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied.
topic prostate cancer
bone scan index
bone scintigraphy
PSMA-PET/CT
url https://www.mdpi.com/1424-8247/10/3/68
work_keys_str_mv AT lenathomas assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT carolinebalmus assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT hojjatahmadzadehfar assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT markusessler assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT holgerstrunk assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT ralphabundschuh assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
_version_ 1724478492200927232